There is overwhelming evidence that platelets from diabetic individuals are hyperreactive, not only when microvascular complications are apparent, but already at an early stage of the disease. There is still controversy about the question of whether primary hyperreactive platelets may contribute to the origin or progression of microangiopathy or whether diabetic platelet hyperfunctionality is just a logical consequence of a continuous low-grade activation of platelets by contact with a diseased microvascular wall. As a consequence of platelet activation, the outer layer of its phospholipid membrane is more procoagulant than in the quiescent state, stimulating thrombin formation in plasma. This platelet function is called platelet procoagulant activity. We studied platelet prothrombinase activity (PPA), a final pathway platelet procoagulant activity of type 1 diabetic platelets, and looked for an eventual correlation with microvascular disease (background retinopathy) and mean platelet volume (MPV). Stypven clotting times (SCTs), reflecting PPA expression, and MPV of citrated platelet-rich plasma (PRP), were measured in 21 patients with type 1 diabetes&mdash;10 with and 11 without background retinopathy&mdash;under clinically acceptable metabolic control and compared them to 20 disease-free voluntary controls. We also compared PPA expression and MPV in diabetic individuals with and without retinopathy. With the SCT, a selective test adapted for studying PPA in PRP, we found hyperexpression of PPA in all diabetic patients. We found no difference in MPV between diabetic and control PRP. Comparing patients with and without background retinopathy we found no significant difference in PPA expression. From these results, we suggest that the phospholipid surface of diabetic platelets, more than the surface of normal control platelets, stimulate the expression of PPA. This diabetic platelet coagulant anomaly was not related to an increased platelet mass (higher MPV) nor to the presence of microangiopathy. We conclude that PPA hyperexpression is associated with patients with type 1 diabetes, already occurring in an early stage of the disease, and not necessarily a consequence of early-stage microvascular disease, because the anomaly is also demonstrable, in the same degree, in patients with diabetes without microangiopathy.
Summary: There is overwhelming evidence that platelets from diabetic individuals are hyperreactive, not only when microvascular complications are apparent, but already at an early stage of the disease. There is still controversy about the question of whether primary hyperreactive platelets may contribute to the origin or progression of microangiopathy or whether diabetic platelet hyperfunctionality is just a logical consequence of a continuous low-grade activation of platelets by contact with a diseased microvascular wall. As a consequence of platelet activation, the outer layer of its phospholipid membrane is more procoagulant than in the quiescent state, stimulating thrombin formation in plasma. This platelet function is called platelet procoagulant activity. We studied platelet prothrombinase activity (PPA), a final pathway platelet procoagulant activity of type 1 diabetic platelets, and looked for an eventual correlation with microvascular disease (background retinopathy) and mean platelet volume (MPV). Stypven clotting times (SCTs), reflecting PPA expression, and MPV of citrated platelet-rich plasma (PRP), were measured in 21 patients with type 1 diabetes&mdash;10 with and 11 without background retinopathy&mdash;under clinically acceptable metabolic control and compared them to 20 disease-free voluntary controls. We also compared PPA expression and MPV in diabetic individuals with and without retinopathy. With the SCT, a selective test adapted for studying PPA in PRP, we found hyperexpression of PPA in all diabetic patients. We found no difference in MPV between diabetic and control PRP. Comparing patients with and without background retinopathy we found no significant difference in PPA expression. From these results, we suggest that the phospholipid surface of diabetic platelets, more than the surface of normal control platelets, stimulate the expression of PPA. This diabetic platelet coagulant anomaly was not related to an increased platelet mass (higher MPV) nor to the presence of microangiopathy. We conclude that PPA hyperexpression is associated with patients with type 1 diabetes, already occurring in an early stage of the disease, and not necessarily a consequence of early-stage microvascular disease, because the anomaly is also demonstrable, in the same degree, in patients with diabetes without microangiopathy. Key Words: Platelet procoagulant activity&mdash;Platelet prothrombinase activity&mdash;Microangiopathy&mdash;Mean platelet volume. Diabetic platelet hyperreactivity, a possible factor in the prethrombotic tendency of diabetic patients, is well documented, even in early diagnosed disease (1) . According to some authors, the finding of hyperfunctionality of diabetic platelets finds its origin in a primary disturbance of bone marrow megakaryopoiesis in diabetes mellitus (2, 3) . Most aspects of diabetic platelet function have been extensively studied, except platelet procoagulant and prothrombinase activities (1) . Besides their role in primary hemostasis, platelets stimulate thrombin generation at sites of vascular injury. When platelets are activated, the asymmetrical phospholipid bilayer of the quiescent state is disturbed and the internally located anionic aminophospholipids phosphatidyl serine and phosphatidyl ethanolamine are externalized, forming an optimal catalytic surface for some basic reactions of the coagulation pathway, especially the activation of factor X (tenase reaction) and factor II (prothrombinase reaction) (4, 5) . Some believe that adenosine diphosphateand collagen-stimulated platelets also contribute to the initial phase of intrinsic coagulation by offering an activating phospholipid surface to the contact activation factors XII and XI (6, 7) . All of these coagulation-promoting activities of the activated platelet phospholipid surface are referred to as platelet procoagulant activity (5) . Platelet prothrombinase activity (PPA) is more specifically defined as the catalyzing activity of platelet phospholipids for the last step of the coagulation cascade, the reaction leading to the transformation of prothrombin (factor II) into thrombin, by the serine protease factor Xa (activated factor X). The aim of the present study was to compare PPA expression of diabetic platelets from patients with type 1 diabetes under acceptable metabolic control and without signs of macroangiopathy, to PPA expression of control platelets from healthy volunteers. Therefore, PPA expression was investigated in plateletrich plasma (PRP) of patients with diabetes and healthy volunteers with the Stypven clotting time (SCT). The SCT of PRP, performed with diluted Russell viper venom solution as a factor X activator (8) , is a sensitive clotting test measuring more specifically the contribution of the anionic platelet phospholipid surface to the last step of the coagulation cascade, i.e., the transformation of prothrombin into thrombin. Hyperexpression of PPA by a hyperfunctional platelet population, as in diabetes, will give rise to shorter SCT clotting times of PRP samples compared to those of PRP samples of controls. We also measured the mean platelet volume (MPV) of the PRP of patients with diabetes and controls and looked for an eventual relationship between PPA expression and MPV and between PPA and the presence of early-stage microvascular disease.
MATERIALS AND METHODS

Patients and controls
We selected 21 patients with type 1 diabetes, 12 men and 9 women, between 24 and 68 years old, who where under acceptable metabolic control without objective signs of macroangiopathy; 10 of them had background retinopathy. We compared their PPA to that of 20 healthy individuals, 12 men and 8 women, between 25 and 65 years old. The time elapsed between diagnosis and study inclusion was 4.82 ± 4.69 years for the patients without retinopathy and 24.40 ± 9.40 years for those with retinopathy. At the time of inclusion, patients with type 1 diabetes without retinopathy had a mean glycosylated hemoglobin (HbA 1 ~) level of 8.66 ± 1.91% and those with retinopathy had a mean glycosylated hemoglobin (HbAl~) level of 9.38 ± 0.91%. Individual patient information is summarized in Table 1 .
Preparation of PRP, platelet counting, and MPV measurement Patient and control PRP were prepared starting from freshly drawn venous blood, taken on Becton-Dickinson Vacutainer (Erembodegem, Belgium) tubes containing trisodium citrate as an anticoagulant, by slow centrifugation at 140 g during 5 minutes. To reach a platelet concentration between 225.109/L and 275.109/L, originally prepared PRP was eventually diluted with equivalent platelet-poor plasma prepared by fast centrifugation (8) with diluted Russell Viper Venom Reagent as factor X activator. One hundred microliters of normal control or patient PRP was added to 100 J.1L of a 10-jjLg/mL diluted Russell Viper Venom reagent (Wellcome, Beckenham, England). The mixture was incubated for 30 seconds in a warm water bath at 37°C, followed by addition of 100 IJ-L of 0.025 M CaCl2 solution and starting the stopwatch. The clotting point was manually determined using a disposable plastic hook. The time lapse in seconds between starting the stopwatch and the clotting point is the SCT.
Statistics
Results of SCT and MPV measurements on PRPs of controls and patients with type 1 diabetes and on PRPs derived from patients with type 1 diabetes with and without background retinopathy were statistically compared with the two-tailed Mann-Whitney U test. A P value of <0.05 was considered statistically significant.
RESULTS
Platelet concentration in PRP was not significantly different between control samples (232 ± 18.109/L, n = 20) and diabetic samples (234 ± 23.109/L, n = 21).
The expression of PPA is inversely related to the SCT. The SCT in PRP was significantly shortened (high PPA expression) in the total group of patients with type 1 diabetes compared to the control group (P = 0.000). The SCT in PRP from patients with diabetes without retinopathy compared to the control group was significantly shortened (P = 0.001). The same was true for the group of patients with diabetes with retinopathy compared to the control group (P = 0.008) ( Table 2 ). Comparing PRP samples of the two subgroups of patients with type 1 diabetes, with and without background retinopathy, no significant differences in SCT clotting times were found ( Table 2 ). No significant differences in MPV of the PRPs were measured between patients with type I diabetes, without or with background retinopathy and the control persons ( Table 2 ).
In summary, the expression of PPA, as measured by the SCT, is significantly higher in PRP of patients with type I diabetes compared to control PRP. No significant difference of PPA in PRP between patients with diabetes with and without early-stage microvascular disease was found.
DISCUSSION
There is consensus for the hypothesis that platelets from patients with diabetes, even in the uncomplicated early phase of the disease, circulate in an activated state. Platelet hyperreactivity may be the consequence of the intrinsic metabolic defect in type I diabetes leading to a primary disturbance of bone marrow megakaryopoiesis and platelet function (2, 3, (9) (10) (11) . Whether hyperfunctional platelets play a significant role in the origin and/or progression of diabetic arterial microvascular disease is a question that is still not completely solved (1, 12, 13) . Most aspects of in vitro diabetic platelet hyperreactivity are well studied and extensively discussed in review articles (1, 3, 9, 12, 13) . Platelet procoagulant activity is a less studied aspect of platelet function in diabetes mel-litus. Two reports deal with platelet procoagulant activity expression in patients with diabetes (14, 15) . Levy-Toledano et al. (14) studied the expression of &dquo;early pathway&dquo; platelet coagulant activities such as &dquo;contact product forming activity&dquo; (6) , &dquo;collagen-induced coagulant activity&dquo; (7) , and total platelet procoagulant activity (with the platelet factor 3 availability test) in 18 patients with diabetes, with and without vascular complications, and compared them to 10 controls. They found a higher expression of total platelet procoagulant activity in both groups of patients with diabetes compared to normal controls. Early pathway coagulant activities were hyperexpressed only in patients with diabetes with vascular complications, whereas they were normal in patients without microangiopathy. Rao et al. (15) studied the expression of early pathway platelet coagulant activities and global platelet procoagulant activity in 39 patients with diabetes with (background, proliferative) and without retinopathy and compared them to 18 patients with nonvascular eye diseases and 38 normal subjects. These authors found significant elevations of four of the five assays in patients with diabetes with proliferative retinopathy, in three of the five assays in patients with background retinopathy, and in only two of the five assays in patients with diabetes without retinopathy. The authors stress that the most significant hyperexpression in diabetes was seen in assays studying early pathway platelet procoagulant activity such as contact product-forming activity and collagen-induced coagulant activity. Rao et al. (15) also describe higher MPV in patients with retinopathy compared to patients with diabetes without retinopathy and found a positive linear relationship between the expression of platelet procoagulant activities and MPV.
We investigated the expression of PPA, a less studied final pathway platelet procoagulant activity, as measured with the SCT in PRP prepared from patients with type 1 diabetes. The present study and our previous communication (16) controls (P = 0.000), and in patients with diabetes without (P = 0.001 ) and with background retinopathy (P = 0.008) compared to the same controls. These findings suggest that in type 1 diabetes, with and without background retinopathy, platelet phospholipid-associated prothrombinase activity is overexpressed. Older studies (14, 15) have shown that early pathway platelet procoagulant activities, such as &dquo;contact product-forming ac-tivity&dquo; (i.e., the capacity of adenosine diphosphatestimulated platelets to activate contact factor XII) (6) and &dquo;collagen-induced coagulant activity&dquo; (i.e., the capacity of collagen-stimulated platelets to activate clotting factor XI) (7) , are hyperexpressed in diabetes mellitus, especially in patients with retinopathy. Our study strongly suggests that the final pathway platelet procoagulant activity, like PPA, also is overexpressed in diabetes.
When measuring MPV in citrated PRP, we found no difference between diabetic samples and normal controls, nor did we find an MPV difference between patients with type 1 diabetes with and without microangiopathy (Table 2 ). We did not find an association between PPA hyperexpression of type 1 diabetic platelets and MPV because we found no significant MPV differences between PRP of patients with diabetes and healthy controls. Our findings suggest that in patients with type I diabetes, hyperexpression of a final pathway platelet procoagulant activity such as PPA is independent of the total size of platelet membrane surface, as quantitated by the MPV, present in PRP. These findings are in contrast to a number of published studies reporting higher MPV in all patients with diabetes, including those without microvascular complications ( 10, 11, (17) (18) (19) (20) , or only in patients with diabetes with microangiopathy (15, 21, 22) compared to control platelets. Two studies are in agreement with our results showing no MPV difference between healthy individuals and patients with diabetes without vascular complications (21 ) and between normal controls and patients with diabetes with retinopathy (23) . Conflicting results about MPV measurement in diabetes may be more or less influenced by interference of the measuring with such technical variables as the use of whole blood or PRP, citrate or EDTA as anticoagulant, the measurement principle such as impedance measuring or light scattering, and finally, the time elapsed between blood withdrawal and MPV measurement.
We conclude that in type 1 diabetes, overexpression of PPA, being a final pathway platelet procoagulant activity, is not related to a larger platelet phospholipid surface (higher MPV) and that this platelet procoagulant anomaly is already present in patients with diabetes without microvascular disease to the same extent as in patients with microangiopathy. Therefore, we suggest that PPA overexpression in patients with type 1 diabetes may be caused by an early-occurring intrinsic qualitative platelet membrane anomaly, in such a way that patients in an early stage of the disease, without microvascular complications, are already affected. Platelet prothrombinase activity hyperexpression of diabetic platelets may play a promoting role, in addition to other aspects of platelet hyperfunctionality, in the well-known prethrombotic state of diabetes mellitus, even in the very early stage of the disease.
